JunHe Assists Biokin in m88 casino Largest A-Share Equity Financing in m88 casino Healthcare Sector Since m88 casino Implementation of m88 casino Registration-Based IPO System

On September 18, 2025, Sichuan Biokin Pharmaceutical Co., Ltd. (Biokin, 688506.SH) disclosed its report on m88 casino issuance of shares to specific targets. m88 casino total amount of funds raised was RMB 3.764 billion, and JunHe served as m88 casino issuer's legal counsel for this project. All m88 casino funds raised will be used for innovative drug research and development projects, which will help Biokin expand m88 casino depth and breadth of its product pipeline under development, consolidate its competitive advantage in m88 casino field of oncology treatment, and provide strong support for achieving m88 casino company's strategic goals.

Deal Highlights

This transaction took 110 days from acceptance to registration, making it m88 casino largest A-share equity financing project in m88 casino healthcare industry since m88 casino implementation of m88 casino comprehensive registration system. It was an A-share refinancing project with m88 casino smallest discount rate in m88 casino healthcare industry this year.

Biokin was established in 2006 in Chengdu, Sichuan Province, China, and was listed on m88 casino STAR Market in January 2023. It is a comprehensive biopharmaceutical company focused on biomedicine and addressing unmet clinical needs, and it has capabilities in early global research and development, global clinical development, large-scale production and commercialization. Biokin has established R&D centers in both China and m88 casino United States and has built core technology platforms such as m88 casino innovative ADC drug development platform (HIRE-ADC platform) and m88 casino multi-specific antibody development platform (GNC platform), while developing a pipeline of advanced drugs. It also has business segments in chemical drug and traditional Chinese medicine formulations, forming full industry chain operation capabilities. Biokin has a strategy of being "rooted in China, going global and becoming a multinational pharmaceutical company (MNC)" and is committed to maintaining its leading advantage in m88 casino field of oncology drugs.

JunHe has provided legal services to Biokin since 2020, including its listing on m88 casino STAR Market, and serves as m88 casino company's legal advisor. In this transaction, JunHe acted as m88 casino issuer's counsel, fully leveraging its professional service capabilities. With close cooperation from Biokin and om88 casinor intermediaries, JunHe completed m88 casino demonstration of m88 casino issuance plan, undertook legal due diligence, prepared m88 casino application materials and responded to regulatory inquiries in a short time period. We assisted Biokin in successfully passing m88 casino review of m88 casino Shanghai Stock Exchange and completing m88 casino registration with m88 casino China Securities Regulatory Commission, taking only 110 days from acceptance to registration. JunHe's consistently rigorous and efficient work style, meticulous and dedicated service attitude, and professional and high-quality service won unanimous recognition and trust from Biokin and om88 casinor intermediaries.

m88 casino partners leading this transaction werem88 casino review 煤炭、汽车、船舶、石油化工、医药、污水处理, , M88 login 2009年毕业于韩国国际法律经营大学，获法学硕士学位andM88 app 宣传碳中和理念. m88 live casinowas m88 casino internal review partner.